Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology 35: Cancer Profiling and Therapeutics

Identification of BCMP11 overexpression in serous borderline ovarian tumor through microarray analysis

Jiyoung Lee, Ke Hao, Joseph Kwong, Ross S. Berkowitz, Michael J. Birrer and Samuel C. Mok
Jiyoung Lee
The Lab of Gynecology Oncology, Dept of Ob-Gyn, Brigham and Women’s Hospital, Boston, MA and National Cancer Institute, Cell and Cancer Biology Branch, Rockville, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke Hao
The Lab of Gynecology Oncology, Dept of Ob-Gyn, Brigham and Women’s Hospital, Boston, MA and National Cancer Institute, Cell and Cancer Biology Branch, Rockville, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Kwong
The Lab of Gynecology Oncology, Dept of Ob-Gyn, Brigham and Women’s Hospital, Boston, MA and National Cancer Institute, Cell and Cancer Biology Branch, Rockville, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ross S. Berkowitz
The Lab of Gynecology Oncology, Dept of Ob-Gyn, Brigham and Women’s Hospital, Boston, MA and National Cancer Institute, Cell and Cancer Biology Branch, Rockville, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Birrer
The Lab of Gynecology Oncology, Dept of Ob-Gyn, Brigham and Women’s Hospital, Boston, MA and National Cancer Institute, Cell and Cancer Biology Branch, Rockville, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel C. Mok
The Lab of Gynecology Oncology, Dept of Ob-Gyn, Brigham and Women’s Hospital, Boston, MA and National Cancer Institute, Cell and Cancer Biology Branch, Rockville, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

2724

Ovarian borderline tumors account for 15% of all epithelial ovarian tumors. In spite of extensive research efforts, the pathogenesis of borderline ovarian tumor is not well understood. We evaluated the gene expression profiles of ovarian borderline tumors to identify genes whose altered expression may influence their clinical behavior. Microarray analysis on serous borderline and invasive ovarian tumors identified breast cancer membrane protein 11(BCMP11), a human homologue of the secreted Xenopus laevis protein XAG, as one of the genes overexpressed in borderline tumors. To validate the expression patterns of BCMP11 in borderline serous ovarian tumors, we performed real-time quantitative PCR and immunohistochemistry. Total messenger RNA was extracted from 10 normal ovarian surface epithelium, 25 microdissected ovarian serous borderline tumors, 6 low grade serous ovarian cancers, and 63 high grade serous ovarian cancers, amplified, and hybridized onto the Affymetrix U133 Plus 2 Oligo microarray. Real-time quantitative PCR was performed on the same RNAs used for microarray analysis. Immunohistochemical staining (IHC) was performed on 36 ovarian serous borderline tumors, 5 low grade ( grade 1 ), 25 high grade ovarian cancers, and 4 normal ovarian epithelium using an anti-BCMP11 antibody. Staining intensity was compared using a semiquantitative scoring system. The intensity of staining was scored as 0, +1, +2, or +3. A total of 110 genes showed significant higher expression in ovarian borderline tumors compared to HOSE and invasive carcinomas. Of these, BCMP11 showed the most significant differences. Real-time quantitative PCR analysis on BCMP11 showed significant overexpression in borderline tumors compared to invasive cancers. There was a significant correlation between qPCR and microarray data (r = 0.753, p < 0.0001). Immunohistochemical analyses demonstrated that BCMP11 protein expression was detected in 0 (0%, score 0) of 4 normal ovarian sections, 37 (90%, score +1, +2 or +3) of 41 borderline and low grade tumor sections and 4 (16%, score +2 or +3) of 25 ovarian cancer sections, respectively. Immunostaining was predominantly restricted to the epithelial tumor cells and especially cytoplasm. Stromal area did not show any positive staining. Our findings provide evidence for a significant association between BCMP11 expression and serous borderline and low-grade ovarian tumor and suggest that BCMP11 protein could be a useful molecular marker for these groups of tumors. Future research assessment of its function and the role of the gene in borderline tumor pathogenesis would be worthwhile.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of BCMP11 overexpression in serous borderline ovarian tumor through microarray analysis
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Identification of BCMP11 overexpression in serous borderline ovarian tumor through microarray analysis
Jiyoung Lee, Ke Hao, Joseph Kwong, Ross S. Berkowitz, Michael J. Birrer and Samuel C. Mok
Cancer Res May 1 2005 (65) (9 Supplement) 641;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Identification of BCMP11 overexpression in serous borderline ovarian tumor through microarray analysis
Jiyoung Lee, Ke Hao, Joseph Kwong, Ross S. Berkowitz, Michael J. Birrer and Samuel C. Mok
Cancer Res May 1 2005 (65) (9 Supplement) 641;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of action associated with response to erbB receptor targeted therapy
  • Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with the sensitivity of gefitinib in recurrence after surgery
  • Genome-wide identification of novel candidate tumor suppressor genes in tumors through a combination of cancer genetic and epigenetic approaches
Show more Cellular and Molecular Biology 35: Cancer Profiling and Therapeutics
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement